Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, Mailstop F–35, Atlanta, GA 30341, telephone (770) 488–7630.

Please refer to Announcement 709 when requesting information and submitting an application.

A copy of "Healthy People 2000" (Full Report; Stock No. 017–001–00474–0) or "Healthy People 2000" (Summary Report; Stock No. 017–001–00473–1) referenced in the "Introduction" may be obtained through the Superintendent of Documents, Government Printing Office, Washington, DC 20402–9325, telephone (202) 512–1800.

Dated: November 6, 1996.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–29141 Filed 11–13–96; 8:45 am] BILLING CODE 4163–18–P

## Hospital Infection Control Practices Advisory Committee: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting. *Name*: Hospital Infection Control Practices Advisory Committee (HICPAC).

Times and Dates: 8:30 a.m.-4:30 p.m., December 12, 1996. 8:30 a.m.-1:30 p.m., December 13, 1996.

*Place:* CDC, Auditorium A, 1600 Clifton Road, NE, Atlanta, Georgia 30333.

*Status:* Open to the public, limited only by the space available.

Purpose: The Committee is charged with providing advice and guidance to the Secretary, the Assistant Secretary for Health, the Director, CDC, and the Director, National Center for Infectious Diseases (NCID), regarding the practice of hospital infection control and strategies for surveillance, prevention, and control of nosocomial infections in U.S. hospitals and updating of guidelines and other policy statements regarding prevention of nosocomial infections.

Matters to be Discussed: Agenda items will include a review of the third draft of the Guideline for Infection Control in Hospital Personnel, the Hospital Infections Program organizational structure and activities, proposed plans and outline for revision of the Guideline for Prevention of Surgical Wound Infections, and an update on CDC activities of interest to the Committee.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Julia S. Garner, Nurse Consultant, Hospital Infections Program, NCID, CDC, 1600 Clifton Road, NE, M/S A–07, Atlanta, Georgia 30333, telephone 404/639–6408.

Dated: November 7, 1996. Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–29139 Filed 11–13–96; 8:45 am] BILLING CODE 4163–18–P

#### Food and Drug Administration

### **Advisory Committees; Renewals**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

SUMMARY: The Food and Drug Administration (FDA) announces the renewal of certain FDA advisory committees by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the charters of the committees listed below for an additional 2 years beyond charter expiration date. The new charters will be in effect until the dates of expiration listed below. This notice is issued under the Federal Advisory Committee Act of October 6, 1972 (Pub. L. 92–463 (5 U.S.C. app. 2)).

**DATES:** Authority for these committees will expire on the dates indicated below unless the Commissioner formally determines that renewal is in the public interest.

Name of committee	Date of expiration
Pulmonary-Allergy Drugs Advisory Committee	May 30, 1998.
Drug Abuse Advisory Committee	May 31, 1998.
Science Advisory Board to the National Center for Toxicological Research	June 2, 1998.
Peripheral and Central Nervous System Drugs Advisory Committee	June 4, 1998.
Psychopharmacologic Drugs Advisory Committee	June 4, 1998.
Science Board to the Food and Drug Administration	June 26, 1998.
Transmissible Spongiform Encephalopathies Advisory Committee (formerly Ad Hoc Advisory Committee on Creutzfeldt- Jakob Disease)	June 9, 1998.
Allergenic Products Advisory Committee	July 9, 1998.
Cardiovascular and Renal Drugs Advisory Committee	August 27, 1998.
Endocrinologic and Metabolic Drugs Advisory Committee	August 27, 1998.
Oncologic Drugs Advisory Committee	September 1, 1998.
Anti-Infective Drugs Advisory Committee	October 7, 1998.
Dermatologic and Ophthalmic Drugs Advisory Committee	October 7, 1998.
Biological Response Modifiers Advisory Committee	October 28, 1998.

#### FOR FURTHER INFORMATION CONTACT:

Donna M. Combs, Committee Management Office (HFA–306), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827– 4820. Dated: November 6, 1996.
Michael A. Friedman,
Deputy Commissioner for Operations.
[FR Doc. 96–29147 Filed 11–13–96; 8:45 am]
BILLING CODE 4160–01–F

#### [Docket No. 96F-0415]

# Nalco/Exxon Energy Chemicals, L. P.; Filing of Food Additive Petition

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing